EpiBiologics

EpiBiologics is a venture-backed biotechnology company based in San Mateo, California, founded in 2021. The company focuses on developing targeted therapies that utilize antibody-based medicines to degrade disease-causing membrane and extracellular proteins. EpiBiologics aims to fill a significant gap in the therapeutic landscape by addressing the 40% of the proteome that is not targeted by traditional intracellular degradation methods.

The company's proprietary EpiTAC platform is central to its approach, utilizing a unique atlas of over 270 degradation-inducing protein receptors. This enables the creation of bispecific antibodies that selectively degrade harmful extracellular proteins while preserving healthy tissue. EpiBiologics is developing its therapies to treat various conditions, including cancer and autoimmune disorders. The leadership team comprises experienced scientists and industry experts, supported by advisors from major pharmaceutical and biotechnology companies. EpiBiologics has successfully raised $73 million in funding to support its innovative research and development efforts.